Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases

BACKGROUND: Central nervous system (CNS) metastases represent a significant source of morbidity and mortality for patients with ALK-positive non-small cell lung cancer (NSCLC). Alectinib has demonstrated robust CNS activity in both crizotinib-naïve and crizotinib-resistant settings. However, the CNS...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Thorac Oncol
Hauptverfasser: Lin, Jessica J., Jiang, Ginger Y., Joshipura, Nencyben, Ackil, Jennifer, Digumarthy, Subba R., Rincon, Sandra P., Yeap, Beow Y., Gainor, Justin F., Shaw, Alice T.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6440803/
https://ncbi.nlm.nih.gov/pubmed/30529198
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2018.12.002
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge